Limits...
The Value of Palliative Gastrectomy for Gastric Cancer Patients With Intraoperatively Proven Peritoneal Seeding.

Yang K, Liu K, Zhang WH, Lu ZH, Chen XZ, Chen XL, Zhou ZG, Hu JK - Medicine (Baltimore) (2015)

Bottom Line: Clinicopathologic variables and survival were compared.The median survivals among the patients with different classifications of peritoneal metastasis were statistically significant (P = 0.000).Results of subgroup analyses showed that except for P3 patients and patients with multisite distant metastases, overall survival was significantly better in patients with palliative gastrectomy, compared with the nonresection group.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Surgery (KY, KL, W-HZ, Z-HL, X-ZC, X-LC, Z-GZ, J-KH); Laboratory of Gastric cancer, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China (KY, KL, W-HZ, Z-HL, X-ZC, X-LC, J-KH).

ABSTRACT
The aim of this study was to evaluate the survival benefit of palliative gastrectomy for gastric cancer patients with peritoneal seeding proven intraoperatively and to identify positive predictive factors for improving survival.The value of palliative resection for gastric cancer patients with peritoneal metastasis is controversial.From 2006 to 2013, 267 gastric cancer patients with intraoperatively identified peritoneal dissemination were retrospectively analyzed. Patients were divided into resection group and nonresection group according to whether a palliative gastrectomy was performed. Clinicopathologic variables and survival were compared. Subgroup analyses stratified by clinicopathologic factors and multivariable analysis for overall survival were also performed.There were 114 patients in the resection group and 153 in nonresection group. The morbidities in the resection and nonresection groups were 14.91% and 5.88%, respectively (P = 0.014). There, however, was no difference in mortality between the 2 groups. The median survival time of patients in the resection group was longer than in nonresection group (14.00 versus 8.57 months, P = 0.000). The median survivals among the patients with different classifications of peritoneal metastasis were statistically significant (P = 0.000). Patients undergoing resection followed by chemotherapy had a significantly longer median survival, compared with that of patients who had chemotherapy alone, those who had resection alone, or those who had not received chemotherapy or resection (P = 0.000). Results of subgroup analyses showed that except for P3 patients and patients with multisite distant metastases, overall survival was significantly better in patients with palliative gastrectomy, compared with the nonresection group. In multivariate analysis, P3 disease (P = 0.000), absence of resection (P = 0.000), and lack of chemotherapy (P = 0.000) were identified as independently associated with poor survival.Palliative gastrectomy might be beneficial to the survival of gastric cancer patients with intraoperatively proven P1/P2 alone, rather than P3. Postoperative palliative chemotherapy could improve survival regardless of operation and should be recommended.

Show MeSH

Related in: MedlinePlus

Survival curves of resection group and nonresection group for gastric cancer patients with intraoperative proven peritoneal seeding (P = 0.000).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4504616&req=5

Figure 1: Survival curves of resection group and nonresection group for gastric cancer patients with intraoperative proven peritoneal seeding (P = 0.000).

Mentions: The median survival was 14.00 (95% CI: 11.53, 16.47) months in the resection group and 8.57 (95% CI: 7.33, 9.81) months in the nonresection group (Figure 1). The survival difference between the 2 groups was significant (P = 0.000). The results of subgroup analyses stratified by clinicopathologic factors showed that except for patients with tumor located at upper third (P = 0.076), P3 patients (P = 0.138) (Figure 2) and patients with multisite distant metastases (P = 0.267) (Figure 3), overall survival was significantly better in patients with palliative gastrectomy compared with the nonresection group, even in patients without postoperative chemotherapy (Figure 4). The results of the subgroup analyses are summarized in Table 2.


The Value of Palliative Gastrectomy for Gastric Cancer Patients With Intraoperatively Proven Peritoneal Seeding.

Yang K, Liu K, Zhang WH, Lu ZH, Chen XZ, Chen XL, Zhou ZG, Hu JK - Medicine (Baltimore) (2015)

Survival curves of resection group and nonresection group for gastric cancer patients with intraoperative proven peritoneal seeding (P = 0.000).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4504616&req=5

Figure 1: Survival curves of resection group and nonresection group for gastric cancer patients with intraoperative proven peritoneal seeding (P = 0.000).
Mentions: The median survival was 14.00 (95% CI: 11.53, 16.47) months in the resection group and 8.57 (95% CI: 7.33, 9.81) months in the nonresection group (Figure 1). The survival difference between the 2 groups was significant (P = 0.000). The results of subgroup analyses stratified by clinicopathologic factors showed that except for patients with tumor located at upper third (P = 0.076), P3 patients (P = 0.138) (Figure 2) and patients with multisite distant metastases (P = 0.267) (Figure 3), overall survival was significantly better in patients with palliative gastrectomy compared with the nonresection group, even in patients without postoperative chemotherapy (Figure 4). The results of the subgroup analyses are summarized in Table 2.

Bottom Line: Clinicopathologic variables and survival were compared.The median survivals among the patients with different classifications of peritoneal metastasis were statistically significant (P = 0.000).Results of subgroup analyses showed that except for P3 patients and patients with multisite distant metastases, overall survival was significantly better in patients with palliative gastrectomy, compared with the nonresection group.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastrointestinal Surgery (KY, KL, W-HZ, Z-HL, X-ZC, X-LC, Z-GZ, J-KH); Laboratory of Gastric cancer, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China (KY, KL, W-HZ, Z-HL, X-ZC, X-LC, J-KH).

ABSTRACT
The aim of this study was to evaluate the survival benefit of palliative gastrectomy for gastric cancer patients with peritoneal seeding proven intraoperatively and to identify positive predictive factors for improving survival.The value of palliative resection for gastric cancer patients with peritoneal metastasis is controversial.From 2006 to 2013, 267 gastric cancer patients with intraoperatively identified peritoneal dissemination were retrospectively analyzed. Patients were divided into resection group and nonresection group according to whether a palliative gastrectomy was performed. Clinicopathologic variables and survival were compared. Subgroup analyses stratified by clinicopathologic factors and multivariable analysis for overall survival were also performed.There were 114 patients in the resection group and 153 in nonresection group. The morbidities in the resection and nonresection groups were 14.91% and 5.88%, respectively (P = 0.014). There, however, was no difference in mortality between the 2 groups. The median survival time of patients in the resection group was longer than in nonresection group (14.00 versus 8.57 months, P = 0.000). The median survivals among the patients with different classifications of peritoneal metastasis were statistically significant (P = 0.000). Patients undergoing resection followed by chemotherapy had a significantly longer median survival, compared with that of patients who had chemotherapy alone, those who had resection alone, or those who had not received chemotherapy or resection (P = 0.000). Results of subgroup analyses showed that except for P3 patients and patients with multisite distant metastases, overall survival was significantly better in patients with palliative gastrectomy, compared with the nonresection group. In multivariate analysis, P3 disease (P = 0.000), absence of resection (P = 0.000), and lack of chemotherapy (P = 0.000) were identified as independently associated with poor survival.Palliative gastrectomy might be beneficial to the survival of gastric cancer patients with intraoperatively proven P1/P2 alone, rather than P3. Postoperative palliative chemotherapy could improve survival regardless of operation and should be recommended.

Show MeSH
Related in: MedlinePlus